



## Press release

### GLSV Co-leads Investment in Neuraxo Biotec

**Munich/Zug**, 19 September 2005 – *Global Life Science Ventures (GLSV)* today announced that it has co-led a €12.8 million Series A financing of Neuraxo Biotec GmbH. The investment was co-led with BioMedinvest AG, with FNI Venture Capital and Mulligan BioCapital AG also participating in the syndicate.

Neuraxo is a biopharmaceutical company founded in 2001 in Dusseldorf, Germany, that focuses on the treatment of nervous system injuries. Neuraxo's key proprietary technology, the Regeneration Promoting Treatment, is the first and only existing drug in development that has been shown to allow the regeneration of injured nerves following their natural nerve tract, thus enabling the recovery of sensory and motor function.

Neuraxo's lead product candidate, Cordaneurin<sup>®</sup>, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication 'treatment of traumatic spinal cord injuries', and will enter clinical trials in December 2005 on patients with acute spinal cord injury. This Series A financing will be used to take Cordaneurin<sup>®</sup> through proof-of-concept studies in man and move additional product candidates into the clinic. Dr. Holger Reithinger, Principal of GLSV, and Dr. Markus Hosang, a Managing Partner at BioMedinvest, will join the company's Supervisory Board.

"We have been impressed by the quality of the data generated by Neuraxo, building on the pioneering research of its founder, Prof. Hans Werner Müller. The important role of the fibrous scar in spinal cord injury and other nervous system injuries was underrated in the past years," said Holger Reithinger.

Hanns-Peter Wiese, Partner at GLSV, remarked: "With this investment, GLSV demonstrates again its focus on identifying and supporting early-stage companies with promising therapeutics in development. Cordaneurin<sup>®</sup> has the potential to greatly improve the prospects for patients with spinal cord injuries."

Dr. Rainer Lichtenberger, CEO of Neuraxo Biotec, commented: "We are very proud to have attracted such a renowned group of investors. Following the granting of Orphan Drug Status to Cordaneurin<sup>®</sup> in 2004, this Series A investment further confirms the excellent value of both our lead product and our proprietary technology platform and pipeline."



**About Global Life Science Ventures:**

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totalling more than €200 million. GLSV has now financed 28 innovative life science companies, eleven of which have completed an exit through IPO, trade sale or M&A. GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

**Global Life Science Ventures**

**Industry-born team – Proven track record – Global perspective**

**Germany**

GLSV GmbH  
Von-der-Tann-Str. 3  
D – 80539 München  
Tel. +49 (0)89 288 151 0  
Fax +49 (0)89 288 151 30  
[www.glsv-vc.com](http://www.glsv-vc.com)  
[mailbox@glsv-vc.com](mailto:mailbox@glsv-vc.com)

**Switzerland**

GLSV AG  
Postplatz 1, P.O. 626  
CH – 6301 Zug  
Tel. +41 (0)41 727 19 40  
Fax +41 (0)41 727 19 45

For additional information, please contact:

**Rochat & Partners**

Christophe Lamps  
Tel. +41 22 718 37 46  
Fax +41 22 786 54 58  
E-mail: [clamps@rochat-pr.ch](mailto:clamps@rochat-pr.ch)